Parathyroid cancer

Czech version

Authors: Ivana Ságová ¹; Matej Stančík ¹; Peter Kentoš ²; Dušan Pávai ²; Daniela Kantárová ¹; Anton Vaňuga ²; Peter Vaňuga ²
Authors‘ workplace: I. Interná klinika JLF UK a UN Martin, Slovenská republika ¹; Národný endokrinologický a diabetologický ústav, Ľubochňa, Slovenská republika ²
Published in: Vnitř Lék 2017; 63(2): 139-144
Category: Case Reports

Overview

Parathyroid cancer is a rare endocrine malignancy, representing less than 1 % of all cases of primary hyperparathyroidism. The exact etiology of the disease remains unknown. Known risk factors include neck irradiation, end stage renal failure, genetic factors, particularly the the HPRT2/CDCT73 gene mutation. The clinical picture is often indolent, yet progressive with a trend of local invasion and metastasis formation in advanced disease. The clinical picture includes symptoms of severe and resistant hypercalcemia, requiring intensive therapy often with the need of dialysis. Radical surgery is the mainstay of the parathyroid cancer treatment. Chemotherapy and radiotherapy are generally ineffective. An early and correct diagnosis of parathyroid carcinoma significantly influences both morbidity and mortality.

Key words:
diagnosis – hyperparathyroidism – parathyroid cancer – treatment

Sources

1. Dudney WC, Bodenner D, Stack BC Jr. Parathyroid carcinoma. Otolaryngol Clin North Am 2010; 43(2): 441–53, xi. Dostupné z DOI: <http://dx.doi.org/10.1016/j.otc.2010.01.011>.

2. Wilkins BJ, Lewis JS Jr. Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol 2009; 3(2): 140–149. Dostupné z DOI: <http://dx.doi.org/10.1007/s12105–009–0115–4>.

3. Ricci G, Assenza M, Barreca M et al. Parathyroid carcinoma: the importance of high clinical suspicion for a correct management. Int J Surg Oncol 2012; 2012: 649148. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/649148>.

4. Shi X, Chang M, Wolf AJ et al. Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol Cell Biol. 1997; 17(3): 1160–1169.

5. Newey PJ, Bowl MR, Thakker RV. Parafibromin – functional insights. J Intern Med 2009; 266(1): 84–98.

6. Jackson CE, Norum RA, Boyd SB et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 1990; 108(6): 1006–1012.

7. Bradley KJ, Hobbs MR, Buley ID et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med 2005; 257(1): 18–26.

8. Chen JD, Morrison C, Zhang C et al. Hyperparathyroidism-jaw tumour syndrome. J Intern Med. 2003; 253(6): 634–642.

9. Givi B, Shah JP. Parathyroid Carcinoma. Clin Oncol (R Coll Radiol) 2010; 22(6): 498–507. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clon.2010.04.007>.

10. Marcocci C, Cetani F, Rubin MR et al. Parathyroid carcinoma. J Bone Miner Res 2008; 23(12): 1869–1880. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.081018>.

11. Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 2001; 86(2): 485–493.

12. Sharretts JM, Kebebew E, Simonds WF. Parathyroid cancer. Semin Oncol 2010; 37(6): 580–590. Dostupné z DOI: <http://dx.doi.org/10.1053/j.seminoncol.2010.10.013>.

13. Kentoš P, Macháleková K, Szépe P et al. Metastazujúci karcinóm prištítneho telieska – zriedkavá príčina primárnej hyperparytyreózy. Onkológia 2008; 3(5): 341–344.

14. Fernandez-Ranvier GG, Khanafshar E, Jensen K et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer 2007; 110(2): 255–264.

15. Bae JH, Choi HJ, Lee Y et al. Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism. J Korean Med Sci 2012; 27(8): 890–895. Dostupné z DOI: <http://dx.doi.org/10.3346/jkms.2012.27.8.890>.

16. Rubin MR, Bilezikian JP, Birken S et al. Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol 2008; 159(4): 469–474. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-08–0169>.

17. Stock JL, Weintraub BD, Rosen SW et al. Human chorionic gonadotropin subunit measurement in primary hyperparathyroidism. J Clin Endocrinol Metab 1982; 54(1): 57–63.

18. Juhlin CC, Villablanca A, Sandelin K et al. Parafibromin immunoreactivity: its use as an additional diagnostics marker for parathyroid tumor classification. Endocrine-Related Cancer 2007; 14(2): 501–512.

19. Rawat N, Khetan N, Williams DW et al. Parathyroid carcinoma. Br J Surg 2005; 92(11): 1345–1353.

20. Roy M, Mazeh H, Chen H et al. Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg 2013; 37(1): 102–106. Dostupné z DOI: <http://dx.doi.org/10.1007/s00268–012–1773-z>.

21. De Feo ML, Colagrande S, Biagini C et al. Parathyroid glands: combination of (99m)Tc MIBI scintigraphy and US for demonstration of parathyroid glands and nodules. Radiology 2000; 214(2): 393–402.

22. Owen RP, Silver CE, Pellitteri PK et al. Parathyroid carcinoma: a review. Head Neck 2011; 33(3): 429–436. Dostupné z DOI: <http://dx.doi.org/10.1002/hed.21376>.

23. Pyzik JP, Matyjaszek-Matuszek B, Zwolak A et al. Parathyroid cancer – difficult diagnosis – a case report. Nucl Med Rev 2016; 19(1): 46–50. Dostupné z DOI: <http://dx.doi.org/10.5603/NMR.2016.0009>.

24. Halenka M, Klusová N, Fryšák Z et al. Karcinom příštítného tělíska, vzácná příčina hyperkalcémie u pacienta s B-NHL. Interní Med 2009; 11(1): 42–44.

25. Lee PK, Jarosek SL, Virnig BA et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 2007; 109(9): 1736–1741.

26. Iihara M, Okamoto T, Suzuki R et al. Functional parathyroid carcinoma: Long-term treatment outcome and risk factor analysis. Surgery 2007; 142(6): 936–943. Erratum in Surgery 2008; 143(2): 302.

27. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol 2001; 2(4): 347–354.

28. Koyano H, Shishiba Y, Shimizu T et al. Successful treatment by surgical removal of bone metastasis producing PTH: new approach to the management of metastatic parathyroid carcinoma. Intern Med 1994; 33(11): 697–702.

29. Flye MW, Brennan MF. Surgical resection of metastatic parathyroid carcinoma. Ann Surg 1981; 193(4): 425–435.

30. Bradwell AR, Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 1999; 353(9150): 370–373.

31. Betea D, Bradwell AR, Harvey TC et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 2004; 89(7): 3413–3420.

32. Lumachi F, Brunello A, Roma A et al. Cancer-induced hypercalcemia. Anticancer Res 2009; 29(5): 1551–1555.

33. Fraker DL. Parathyroid tumors. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and practice of oncology. Lippincott Williams and Wilkins: Philadelphia 2000: 1763–1769.

34. Koea JB, Shaw HF. Parathyroid Cancer: Biology and management. Surg Oncol 1999; 8(3): 155–165.

35. Jakoubkova S, Vokurka J, Cap J et al. Parathyroid carcinoma: Clinical presentation and treatment. International Congress Series 2003; 1240: 991–995.

Labels

Diabetology Endocrinology Internal medicine

Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm

Acute kidney injury: a current comprehensive overview

Autoantibodies in systemic connective tissue disease and ANCA-associated vasculitis, their relationship to interstitial lung diseases and prognosis

An assessment of VO2 kinetics in the recovery phase of cardiopulmonary exercise test in patients with heart disease – importance and classification

Functional impact of hERG: from physiological role to target of anticancer therapy

Antiplatelet thromboprophylaxis of arterial vascular diseases and organovascular ischemic diseases

Conservative treatment of late aortic graft infection

Article was published in

Internal Medicine

2017 Issue 2